Hologic, Inc. (NASDAQ:HOLX) Shares Purchased by Greenleaf Trust

Greenleaf Trust boosted its stake in Hologic, Inc. (NASDAQ:HOLX) by 13.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 5,147 shares of the medical equipment provider’s stock after acquiring an additional 623 shares during the quarter. Greenleaf Trust’s holdings in Hologic were worth $368,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in HOLX. McGlone Suttner Wealth Management Inc. acquired a new stake in Hologic during the 4th quarter worth $27,000. Venturi Wealth Management LLC acquired a new stake in Hologic during the 3rd quarter worth $29,000. NBC Securities Inc. acquired a new stake in Hologic during the 3rd quarter worth $33,000. Deseret Mutual Benefit Administrators boosted its stake in Hologic by 42.2% during the 3rd quarter. Deseret Mutual Benefit Administrators now owns 522 shares of the medical equipment provider’s stock worth $36,000 after purchasing an additional 155 shares during the last quarter. Finally, Massmutual Trust Co. FSB ADV boosted its stake in Hologic by 69.4% during the 4th quarter. Massmutual Trust Co. FSB ADV now owns 554 shares of the medical equipment provider’s stock worth $40,000 after purchasing an additional 227 shares during the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Stock Up 1.3 %

Shares of HOLX opened at $77.19 on Wednesday. The firm has a market cap of $18.12 billion, a P/E ratio of 36.58, a price-to-earnings-growth ratio of 2.55 and a beta of 1.00. Hologic, Inc. has a 12-month low of $64.02 and a 12-month high of $87.88. The company’s 50-day moving average price is $75.87 and its 200 day moving average price is $72.69. The company has a current ratio of 3.89, a quick ratio of 3.18 and a debt-to-equity ratio of 0.55.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Thursday, February 1st. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.95 by $0.03. The firm had revenue of $1.01 billion for the quarter, compared to analyst estimates of $989.32 million. Hologic had a net margin of 12.98% and a return on equity of 18.91%. Hologic’s revenue was down 5.7% on a year-over-year basis. During the same period in the previous year, the firm earned $1.07 EPS. On average, sell-side analysts forecast that Hologic, Inc. will post 4.01 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. William Blair reaffirmed an “outperform” rating on shares of Hologic in a research note on Friday, February 2nd. Needham & Company LLC reaffirmed a “buy” rating and set a $90.00 target price on shares of Hologic in a research note on Wednesday, April 10th. Raymond James lifted their price target on Hologic from $85.00 to $88.00 and gave the stock an “outperform” rating in a report on Friday, February 2nd. UBS Group lifted their price target on Hologic from $78.00 to $79.00 and gave the stock a “neutral” rating in a report on Friday, February 2nd. Finally, Evercore ISI lifted their price target on Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a report on Thursday, April 4th. Six research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $87.00.

Insider Activity at Hologic

In related news, Director Charles J. Dockendorff sold 1,465 shares of the business’s stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $76.21, for a total value of $111,647.65. Following the sale, the director now directly owns 1,572 shares in the company, valued at approximately $119,802.12. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Hologic news, Director Charles J. Dockendorff sold 1,465 shares of the business’s stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $76.21, for a total transaction of $111,647.65. Following the sale, the director now directly owns 1,572 shares in the company, valued at $119,802.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Karleen Marie Oberton sold 14,940 shares of the business’s stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $75.00, for a total transaction of $1,120,500.00. Following the sale, the chief financial officer now owns 103,916 shares in the company, valued at $7,793,700. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 32,846 shares of company stock worth $2,473,443. Company insiders own 1.75% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.